EN IT

Oncologia Personalizzata

XEPTAGEN SpA è attivamente impegnata nella scoperta e nella validazione di nuovi marcatori per migliorare la gestione clinica del paziente oncologico sviluppando trattamenti terapeutici personalizzati.

Products Highlight

Latest Product Literature

Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. Int J Biol Markers. eISSN 1724-6008. 2018.

The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma. Dig Liver Dis. 50(S1):47. 2018.

Low levels of squamous cell carcinoma antigen–IgM complexes in serum are predictors of better survival in patients with liver cirrhosis. Dig Liver Dis. 50(S1):42. 2018.

Serum and bile squamous cell carcinoma antigen detection: a new prognostic marker in patients with perihilar cholangiocarcinoma. Dig Liver Dis. 50(S1):40. 2018.

Role of SERPINB3 like serological and molecular biomarker into NASH development and progression. Dig Liver Dis. 50(S1):18. 2018.

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society. EuroBiotech J. 2(1):30-34. 2018.


Comunicati stampa

Youtube

Tweets by Xeptagen